Studying NWRD09 for women with persistent HPV16 infection
Part of Infections, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called NWRD09 for women with long-lasting HPV type 16 infection that hasn't gone away. The goal is to see if it can help clear the virus and prevent precancerous changes from becoming cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 60.
- Have a confirmed HPV type 16 infection that has lasted 6 months or longer.
- Recent Pap test shows high-grade changes (ASC-H or HSIL) that need further evaluation.
- A satisfactory colposcopy exam (a close look at the cervix) at the time of screening.
- Agree to use effective birth control during the study if you can become pregnant.
- Not have certain heart conditions, active infections, or use of immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (NWRD09) for people who have had HPV type 16 infection in the anal area for over a year. It aims to see if the drug can help clear the virus without causing serious side effects.
This trial tests an experimental treatment called NWRD09 for women who have had a persistent HPV 16 infection for at least 12 months. The goal is to see if it can clear the virus and prevent cervical changes.
This trial tests a new drug called NWRD09 for women with high-grade cervical cell changes (CIN 2/3) caused by HPV type 16. The goal is to see if the drug can help clear these abnormal cells without needing surgery.
This study tests an investigational drug called NWRD09 in women with high-grade cervical lesions caused by HPV16. The goal is to see if it can help eliminate the abnormal cells and reduce the risk of cervical cancer.
This study tests a new treatment (NWRD08) for women with high-grade cervical changes (CIN 2/3) caused by HPV types 16 or 18. It aims to see if the treatment can help clear the abnormal cells and prevent them from becoming cancer.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
Hear when a new Persistent HPV16 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.